

SUPPLEMENTAL MATERIAL

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| Supplementary Table 1. Baseline characteristics of study participants and the participants who were excluded from the analysis due to missing data |2 |
| Supplementary Table 2. Median value (interquartile range) of HOMA-IR according to glucose tolerance status |3 |
| Supplementary Table 3. Baseline blood pressures and lipids of participants according to HOMA-IR quartiles stratified by glucose tolerance status |4 |
| Supplementary Table 4. Hazard ratio (95% CI) of CVD events associated with insulin resistance among overall participants |5 |
| Supplementary Table 5. Hazard ratio (95% CI) of CVD events associated with insulin resistance according to glucose tolerance status defined by different combinations of glycemic parameters |6 |
| Supplementary Table 6. Median value (interquartile range) of HOMA-IR and hazard ratio (95% CI) of CVD events associated with insulin resistance among participants with diabetes taking or not taking hypoglycemic pharmacologic therapy |8 |
| Supplementary Table 7. Hazard ratio (95% CI) of CVD events associated with insulin resistance in prediabetes or diabetes compared with the overall normal glucose tolerance defined by different combinations of glycemic parameters |9 |
| Supplementary Table 8. Hazard ratio (95% CI) of CVD events associated with insulin resistance and obesity in prediabetes or diabetes compared with the overall normal glucose tolerance defined by different combinations of glycemic parameters |11 |
| Supplementary Table 9. Hazard ratio (99% CI) of CVD events associated with insulin resistance and the combination of insulin resistance and obesity |13 |
| Supplementary Figure 1. Hazard ratio (95% CI) of CVD events associated with insulin resistance and general obesity among participants with prediabetes or diabetes compared with the overall participants with normal glucose tolerance |15 |
| Supplementary Figure 2. Hazard ratio (95% CI) of CVD events associated with insulin resistance and abdominal obesity among participants with prediabetes or diabetes compared with the overall participants with normal glucose tolerance |16 |

Supplementary Table 1. Baseline characteristics of study participants and the participants who were excluded from the analysis due to missing data

| Characteristic | Study participants | Excluded participants with missing data* |
|-------------------------------|---------------------------|-------------------------------------------------|
| Number of participants | 111576 | 34522 |
| Age, years | 56.1 (9.0) | 56.3 (8.8) |
| Sex, n (%) | | |
| Men | 38005 (34.1) | 11407 (33.0) |
| Women | 73571 (65.9) | 23115 (67.0) |
| BMI, kg/m ² | 24.4 (3.3) | 25.0 (3.4) |
| Waist circumference, cm | 83.6 (9.8) | 84.3 (9.7) |
| Fasting plasma glucose, mg/dL | 103.0 (21.8) | 103.3 (23.8) |
| HbA1c, % | 5.8 (0.8) | 5.9 (0.8) |
| HOMA-IR | 1.7 (1.1-2.4) | 1.7 (1.2-2.5) |

Values are mean (SD) for continuous variables with normal distribution, median (interquartile range) for continuous variables with skewed distribution, and number (proportion) for categorical variables.

*There were 15,504 participants with missing data on baseline HOMA-IR or glucose tolerance status and 19,018 participants whose information on ascertainment of incident CVD during follow-up was not available.

Abbreviations: BMI=body mass index; HbA1c=hemoglobin A1c; HOMA-IR=homoeostasis model assessment of insulin resistance.

Supplementary Table 2. Median value (interquartile range) of HOMA-IR according to glucose tolerance status

| Glucose tolerance status | Sex-specific quartile of HOMA-IR* | | | | | | | |
|-----------------------------------------------------------------------------------|-----------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| | Quartile 1 | | Quartile 2 | | Quartile 3 | | Quartile 4 | |
| | Men | Women | Men | Women | Men | Women | Men | Women |
| Glucose tolerance status defined by fasting glucose, 2h glucose, and HbA1c | | | | | | | | |
| Normal glucose tolerance (n=28890) | 0.57 (0.43-0.69) | 0.80 (0.65-0.91) | 0.97 (0.88-1.06) | 1.18 (1.09-1.27) | 1.39 (1.27-1.53) | 1.57 (1.46-1.70) | 2.20 (1.89-2.71) | 2.31 (2.05-2.78) |
| Prediabetes (n=64972) | 0.76 (0.58-0.90) | 1.00 (0.81-1.14) | 1.25 (1.13-1.37) | 1.51 (1.39-1.63) | 1.80 (1.64-1.98) | 2.06 (1.90-2.23) | 2.83 (2.45-3.49) | 3.09 (2.71-3.75) |
| Diabetes (n=17714) | 1.02 (0.75-1.24) | 1.39 (1.10-1.61) | 1.91 (1.68-2.13) | 2.25 (2.04-2.45) | 2.89 (2.60-3.24) | 3.21 (2.94-3.52) | 4.93 (4.16-6.31) | 5.12 (4.41-6.49) |
| Glucose tolerance status defined by fasting and 2h glucose | | | | | | | | |
| Normal glucose tolerance (n=50632) | 0.59 (0.45-0.71) | 0.82 (0.67-0.93) | 0.98 (0.90-1.08) | 1.22 (1.12-1.31) | 1.41 (1.29-1.56) | 1.62 (1.51-1.76) | 2.22 (1.92-2.72) | 2.39 (2.11-2.86) |
| Prediabetes (n=46752) | 0.85 (0.65-1.00) | 1.14 (0.93-1.29) | 1.38 (1.26-1.51) | 1.70 (1.56-1.83) | 1.97 (1.80-2.16) | 2.29 (2.12-2.48) | 3.05 (2.66-3.79) | 3.40 (3.00-4.09) |
| Diabetes (n=14188) | 1.05 (0.75-1.28) | 1.48 (1.16-1.72) | 2.00 (1.75-2.23) | 2.40 (2.20-2.63) | 3.02 (2.73-3.38) | 3.44 (3.16-3.81) | 5.11 (4.36-6.62) | 5.47 (4.74-6.90) |
| Glucose tolerance status defined by fasting glucose and HbA1c | | | | | | | | |
| Normal glucose tolerance (n=32032) | 0.65 (0.49-0.79) | 0.89 (0.73-1.03) | 1.08 (0.94-1.24) | 1.33 (1.18-1.52) | 1.55 (1.34-1.73) | 1.78 (1.55-2.02) | 2.40 (1.99-2.92) | 2.60 (2.16-3.09) |
| Prediabetes (n=65851) | 0.79 (0.60-0.94) | 1.05 (0.86-1.21) | 1.28 (1.14-1.42) | 1.55 (1.40-1.70) | 1.83 (1.65-2.03) | 2.11 (1.92-2.32) | 2.87 (2.46-3.59) | 3.14 (2.73-3.88) |
| Diabetes (n=13691) | 1.00 (0.70-1.36) | 1.32 (1.04-1.65) | 2.03 (1.69-2.30) | 2.24 (1.96-2.54) | 2.99 (2.62-3.45) | 3.19 (2.45-3.61) | 4.78 (3.99-6.17) | 4.85 (4.03-6.21) |
| Glucose tolerance status defined by 2h glucose and HbA1c | | | | | | | | |
| Normal glucose tolerance (n=37554) | 0.63 (0.47-0.75) | 0.84 (0.68-0.96) | 1.06 (0.95-1.16) | 1.25 (1.16-1.35) | 1.52 (1.38-1.68) | 1.69 (1.56-1.83) | 2.43 (2.10-3.02) | 2.53 (2.22-3.08) |
| Prediabetes (n=57987) | 0.75 (0.57-0.89) | 0.99 (0.80-1.13) | 1.25 (1.13-1.38) | 1.50 (1.38-1.63) | 1.82 (1.66-2.01) | 2.07 (1.91-2.25) | 2.92 (2.51-3.64) | 3.13 (2.74-3.83) |
| Diabetes (n=16034) | 1.00 (0.72-1.22) | 1.37 (1.09-1.59) | 1.87 (1.64-2.09) | 2.22 (2.01-2.42) | 2.84 (2.56-3.17) | 3.17 (2.90-3.47) | 4.78 (4.04-6.04) | 5.03 (4.35-6.29) |

Glucose tolerance status was defined by different combinations of glycemic parameters along with a self-reported previous diagnosis of diabetes by health care professionals, according to the American Diabetes Association 2010 criteria. There were 111576 participants included in the analysis of glucose tolerance status defined by all three glycemic measures. The number of missing value was 4 for definition by fasting and 2h glucose, 2 for definition by fasting glucose and HbA1c, and 1 for definition by 2h glucose and HbA1c.

*Sex-specific quartiles of HOMA-IR were defined among participants with normal glucose tolerance, prediabetes, and diabetes, separately.

Abbreviations: HbA1c=hemoglobin A1c; HOMA-IR=homoeostasis model assessment of insulin resistance.

Supplementary Table 3. Baseline blood pressures and lipids of participants according to HOMA-IR quartiles stratified by glucose tolerance status

| Characteristic | Sex-specific HOMA-IR quartile* | | | |
|-------------------------------------------|--------------------------------|---------------|---------------|---------------|
| | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 |
| Normal glucose tolerance (n=28890) | | | | |
| Blood pressure | | | | |
| Systolic blood pressure, mmHg | 127 (21) | 128 (21) | 129 (20) | 132 (20) |
| Diastolic blood pressure, mmHg | 75 (11) | 76 (11) | 78 (11) | 80 (11) |
| Lipid profile | | | | |
| Total cholesterol, mg/dL | 181.1 (38.9) | 182.3 (40.6) | 186.3 (41.1) | 189.2 (42.3) |
| LDL cholesterol, mg/dL | 100.2 (30.1) | 103.8 (31.5) | 107.6 (32.0) | 110.1 (32.7) |
| HDL cholesterol, mg/dL | 58.1 (14.7) | 54.9 (13.9) | 52.5 (13.4) | 49.5 (12.6) |
| Triglycerides, mg/dL | 96.1 (63.6) | 106.3 (65.0) | 124.5 (83.4) | 153.2 (106.9) |
| Prediabetes (n=64972) | | | | |
| Blood pressure | | | | |
| Systolic blood pressure, mmHg | 129 (22) | 131 (20) | 133 (20) | 136 (20) |
| Diastolic blood pressure, mmHg | 76 (11) | 78 (11) | 80 (11) | 82 (11) |
| Lipid profile | | | | |
| Total cholesterol, mg/dL | 187.4 (42.6) | 190.3 (43.7) | 193.6 (44.5) | 196.0 (44.7) |
| LDL cholesterol, mg/dL | 106.2 (32.4) | 110.4 (33.1) | 113.2 (34.1) | 114.4 (34.5) |
| HDL cholesterol, mg/dL | 56.7 (15.3) | 52.7 (14.0) | 50.3 (13.0) | 47.5 (12.3) |
| Triglycerides, mg/dL | 106.7 (71.7) | 127.6 (82.6) | 150.5 (103.4) | 182.6 (125.6) |
| Diabetes (n=17714) | | | | |
| Blood pressure | | | | |
| Systolic blood pressure, mmHg | 135 (22) | 138 (21) | 140 (20) | 142 (21) |
| Diastolic blood pressure, mmHg | 78 (11) | 81 (11) | 82 (11) | 84 (11) |
| Lipid profile | | | | |
| Total cholesterol, mg/dL | 194.9 (47.0) | 196.8 (46.6) | 200.1 (48.1) | 201.6 (47.4) |
| LDL cholesterol, mg/dL | 111.4 (35.2) | 114.7 (34.7) | 116.6 (36.1) | 116.8 (35.6) |
| HDL cholesterol, mg/dL | 54.4 (16.1) | 48.9 (12.8) | 47.2 (12.3) | 46.1 (11.7) |
| Triglycerides, mg/dL | 134.3 (104.5) | 171.7 (123.7) | 197.6 (141.3) | 219.7 (157.9) |

Values are mean (SD). Glucose tolerance status was defined by all three glycemic parameters along with a self-reported previous diagnosis of diabetes by health care professionals, according to the ADA 2010 criteria. SI conversion factors: To convert LDL, HDL, and total cholesterol to mmol/L, multiply by 0.0259; and triglycerides to mmol/L, multiply by 0.0113.

*Sex-specific quartiles of HOMA-IR were defined among participants with normal glucose tolerance, prediabetes, and diabetes, separately.

Abbreviations: HDL=high-density lipoprotein; HOMA-IR=homoeostasis model assessment of insulin resistance; LDL=low-density lipoprotein.

Supplementary Table 4. Hazard ratio (95% CI) of CVD events associated with insulin resistance among overall participants

| Category | Person-years | Cases | HR (95% CI) | | |
|--------------------------------|--------------|-------|------------------|------------------|------------------|
| | | | Model 1* | Model 2† | Model 3‡ |
| HOMA-IR quartile | | | | | |
| Quartile 1 | 100437 | 653 | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) |
| Quartile 2 | 100248 | 556 | 0.91 (0.81-1.02) | 0.91 (0.81-1.02) | 0.90 (0.80-1.01) |
| Quartile 3 | 100977 | 627 | 1.01 (0.91-1.13) | 1.00 (0.90-1.12) | 0.99 (0.89-1.11) |
| Quartile 4 | 100494 | 872 | 1.36 (1.22-1.50) | 1.30 (1.17-1.45) | 1.29 (1.16-1.44) |
| Each 1-SD increment in HOMA-IR | - | - | 1.15 (1.11-1.19) | 1.13 (1.09-1.17) | 1.14 (1.10-1.18) |

There were 111576 participants included in the analysis. Insulin resistance was assessed by sex-specific quartiles of HOMA-IR or sex-specific 1-SD of HOMA-IR (1-SD of HOMA-IR equals to 1.23 in men and 1.18 in women).

*Model 1 was adjusted for age, sex, education attainment (below high school, high school or above), alcohol drinking status (never, former, current), smoking status (never, former, current), physical activity (inactive, insufficiently active, active), and diet quality score.

†Model 2 was further adjusted for HbA1c, on the basis of Model 1.

‡Model 3 was further adjusted for glucose tolerance status (normal glucose tolerance, prediabetes, diabetes), on the basis of Model 1.

Abbreviations: CI=confidence interval; CVD=cardiovascular disease; HOMA-IR=homoeostasis model assessment of insulin resistance; HR=hazard ratio; SD=standard deviation.

Supplementary Table 5. Hazard ratio (95% CI) of CVD events associated with insulin resistance according to glucose tolerance status defined by different combinations of glycemic parameters

| Category | Normal glucose tolerance | | | Prediabetes | | | Diabetes | | |
|----------------------------------------------------------------------|--------------------------|-------|------------------|--------------|-------|------------------|--------------|-------|------------------|
| | Person-years | Cases | HR (95% CI)* | Person-years | Cases | HR (95% CI)* | Person-years | Cases | HR (95% CI)* |
| Glucose tolerance status defined by fasting and 2h glucose | | | | | | | | | |
| HOMA-IR quartile† | | | | | | | | | |
| Quartile 1 | 46060 | 285 | 1.00 (Ref.) | 41134 | 263 | 1.00 (Ref.) | 12571 | 130 | 1.00 (Ref.) |
| Quartile 2 | 46037 | 245 | 0.94 (0.79-1.12) | 41250 | 244 | 1.01 (0.84-1.20) | 12648 | 105 | 0.88 (0.68-1.13) |
| Quartile 3 | 46454 | 253 | 0.99 (0.84-1.18) | 41764 | 281 | 1.17 (0.99-1.39) | 12575 | 150 | 1.29 (1.02-1.64) |
| Quartile 4 | 46878 | 271 | 1.05 (0.88-1.24) | 42035 | 312 | 1.30 (1.10-1.53) | 12736 | 169 | 1.42 (1.13-1.79) |
| P value for trend | - | - | 0.50 | - | - | 0.0006 | - | - | 0.0001 |
| Each 1-SD increment in HOMA-IR‡ | - | - | 1.07 (0.98-1.16) | - | - | 1.14 (1.08-1.21) | - | - | 1.13 (1.07-1.19) |
| Glucose tolerance status defined by fasting glucose and HbA1c | | | | | | | | | |
| HOMA-IR quartile† | | | | | | | | | |
| Quartile 1 | 29166 | 176 | 1.00 (Ref.) | 58722 | 394 | 1.00 (Ref.) | 12122 | 94 | 1.00 (Ref.) |
| Quartile 2 | 29026 | 154 | 0.98 (0.79-1.21) | 58762 | 332 | 0.92 (0.80-1.07) | 12239 | 94 | 1.01 (0.76-1.34) |
| Quartile 3 | 29414 | 160 | 1.03 (0.83-1.27) | 59250 | 368 | 1.03 (0.90-1.19) | 12146 | 141 | 1.57 (1.21-2.04) |
| Quartile 4 | 29759 | 185 | 1.17 (0.95-1.45) | 59281 | 446 | 1.26 (1.10-1.45) | 12262 | 164 | 1.79 (1.39-2.31) |
| P value for trend | - | - | 0.12 | - | - | 0.0003 | - | - | <0.0001 |
| Each 1-SD increment in HOMA-IR‡ | - | - | 1.11 (0.99-1.23) | - | - | 1.12 (1.06-1.18) | - | - | 1.18 (1.11-1.25) |
| Glucose tolerance status defined by 2h glucose and HbA1c | | | | | | | | | |
| HOMA-IR quartile† | | | | | | | | | |
| Quartile 1 | 33928 | 198 | 1.00 (Ref.) | 52188 | 342 | 1.00 (Ref.) | 14227 | 128 | 1.00 (Ref.) |
| Quartile 2 | 33647 | 167 | 0.94 (0.77-1.16) | 52187 | 307 | 0.99 (0.84-1.15) | 14351 | 130 | 1.06 (0.83-1.35) |
| Quartile 3 | 33909 | 169 | 0.98 (0.80-1.21) | 52533 | 344 | 1.11 (0.95-1.29) | 14331 | 147 | 1.24 (0.98-1.58) |
| Quartile 4 | 34030 | 185 | 1.06 (0.87-1.30) | 52343 | 402 | 1.32 (1.14-1.53) | 14478 | 189 | 1.60 (1.28-2.01) |
| P value for trend | - | - | 0.52 | - | - | <0.0001 | - | - | <0.0001 |
| Each 1-SD increment in HOMA-IR‡ | - | - | 1.06 (0.97-1.16) | - | - | 1.15 (1.09-1.21) | - | - | 1.13 (1.07-1.20) |

Glucose tolerance status was defined by different combinations of glycemic parameters along with a self-reported previous diagnosis of diabetes by health care professionals, according to the ADA 2010 criteria. There were 111572 participants included in the analysis of glucose tolerance

status defined by fasting and 2h glucose (normal glucose tolerance, n=50632; prediabetes, n=46752; diabetes, n=14188), 111574 participants included in the analysis of glucose tolerance status defined by fasting glucose and HbA1c (normal glucose tolerance, n=32032; prediabetes, n=65851; diabetes, n=13691), and 111575 participants included in the analysis of glucose tolerance status defined by 2h glucose and HbA1c (normal glucose tolerance, n=37554; prediabetes, n=57987; diabetes, n=16034).

*HRs (95% CIs) were adjusted for age, sex, education attainment (below high school, high school or above), alcohol drinking status (never, former, current), smoking status (never, former, current), physical activity (inactive, insufficiently active, active), and diet quality score.

†Sex-specific quartiles of HOMA-IR were defined among participants with normal glucose tolerance, prediabetes, and diabetes, separately.

‡1-SD of HOMA-IR was 1.23 in men and 1.18 in women. P value for interaction between each 1-SD increment in HOMA-IR and glucose tolerance status on CVD risk was 0.022 for glucose tolerance status defined by fasting and 2h glucose, 0.011 for glucose tolerance status defined by fasting glucose and HbA1c, and 0.093 for glucose tolerance status defined by 2h glucose and HbA1c.

Abbreviations: CI=confidence interval; CVD=cardiovascular disease; HbA1c=hemoglobin A1c; HOMA-IR=homoeostasis model assessment of insulin resistance; HR=hazard ratio; SD=standard deviation.

Supplementary Table 6. Median value (interquartile range) of HOMA-IR and hazard ratio (95% CI) of CVD events associated with insulin resistance among participants with diabetes taking or not taking hypoglycemic pharmacologic therapy

| Category | Median (IQR) | Person-years | Cases | HR (95% CI)* |
|-------------------------------------------------------------------------|------------------|--------------|-------|------------------|
| Overall diabetes (n=27022) | | | | |
| HOMA-IR quartile† | | | | |
| Quartile 1 | 1.28 (0.99-1.53) | 24034 | 250 | 1.00 (Ref.) |
| Quartile 2 | 2.20 (1.98-2.42) | 24052 | 257 | 1.08 (0.91-1.29) |
| Quartile 3 | 3.23 (2.93-3.59) | 24036 | 320 | 1.37 (1.16-1.61) |
| Quartile 4 | 5.45 (4.61-7.26) | 24394 | 377 | 1.56 (1.33-1.83) |
| P for trend | - | - | - | <0.0001 |
| Diabetes not taking hypoglycemic pharmacologic therapy (n=17714) | | | | |
| HOMA-IR quartile† | | | | |
| Quartile 1 | 1.23 (0.93-1.48) | 15681 | 139 | 1.00 (Ref.) |
| Quartile 2 | 2.13 (1.91-2.34) | 15847 | 135 | 1.02 (0.81-1.30) |
| Quartile 3 | 3.10 (2.82-3.42) | 15769 | 172 | 1.36 (1.08-1.70) |
| Quartile 4 | 5.04 (4.33-6.42) | 15944 | 207 | 1.61 (1.30-2.00) |
| P for trend | - | - | - | <0.0001 |
| Diabetes taking hypoglycemic pharmacologic therapy (n=9308) | | | | |
| HOMA-IR quartile† | | | | |
| Quartile 1 | 1.38 (1.10-1.65) | 8255 | 118 | 1.00 (Ref.) |
| Quartile 2 | 2.36 (2.12-2.62) | 8278 | 124 | 1.07 (0.83-1.38) |
| Quartile 3 | 3.51 (3.17-3.95) | 8279 | 152 | 1.29 (1.01-1.64) |
| Quartile 4 | 6.56 (5.24-9.33) | 8464 | 157 | 1.30 (1.02-1.65) |
| P for trend | - | - | - | 0.012 |

*HRs (95% CIs) were adjusted for age, sex, education attainment (below high school, high school or above), alcohol drinking status (never, former, current), smoking status (never, former, current), physical activity (inactive, insufficiently active, active), and diet quality score.

†Sex-specific quartiles of HOMA-IR were defined among overall participants with diabetes and among participants with diabetes taking or not taking hypoglycemic pharmacologic therapy, separately.

Abbreviations: CI=confidence interval; CVD=cardiovascular disease; HOMA-IR=homoeostasis model assessment of insulin resistance; HR=hazard ratio; IQR=interquartile range.

Supplementary Table 7. Hazard ratio (95% CI) of CVD events associated with insulin resistance in prediabetes or diabetes compared with the overall normal glucose tolerance defined by different combinations of glycemic parameters

| Category | Person-years | Cases | HR (95% CI)* |
|----------------------------------------------------------------------|--------------|-------|------------------|
| Glucose tolerance status defined by fasting and 2h glucose | | | |
| Normal glucose tolerance (n=50632) | 185429 | 1054 | 1.00 (Ref.) |
| Prediabetes (n=46752) | | | |
| HOMA-IR quartile† | | | |
| Quartile 1 | 41134 | 263 | 0.89 (0.78-1.02) |
| Quartile 2 | 41250 | 244 | 0.90 (0.78-1.03) |
| Quartile 3 | 41764 | 281 | 1.05 (0.92-1.20) |
| Quartile 4 | 42035 | 312 | 1.16 (1.03-1.32) |
| Diabetes (n=14188) | | | |
| HOMA-IR quartile† | | | |
| Quartile 1 | 12571 | 130 | 1.23 (1.03-1.48) |
| Quartile 2 | 12648 | 105 | 1.08 (0.88-1.32) |
| Quartile 3 | 12575 | 150 | 1.61 (1.36-1.92) |
| Quartile 4 | 12736 | 169 | 1.76 (1.50-2.07) |
| Glucose tolerance status defined by fasting glucose and HbA1c | | | |
| Normal glucose tolerance (n=32032) | 117366 | 675 | 1.00 (Ref.) |
| Prediabetes (n=65851) | | | |
| HOMA-IR quartile† | | | |
| Quartile 1 | 58722 | 394 | 0.89 (0.79-1.01) |
| Quartile 2 | 58763 | 332 | 0.82 (0.72-0.93) |
| Quartile 3 | 59250 | 368 | 0.92 (0.81-1.04) |
| Quartile 4 | 59281 | 446 | 1.12 (0.99-1.26) |
| Diabetes (n=13691) | | | |
| HOMA-IR quartile† | | | |
| Quartile 1 | 12122 | 94 | 0.93 (0.75-1.15) |
| Quartile 2 | 12239 | 94 | 0.94 (0.76-1.17) |
| Quartile 3 | 12146 | 141 | 1.48 (1.23-1.77) |
| Quartile 4 | 12262 | 164 | 1.67 (1.41-1.98) |
| Glucose tolerance status defined by 2h glucose and HbA1c | | | |
| Normal glucose tolerance (n=37554) | 135515 | 719 | 1.00 (Ref.) |
| Prediabetes (n=57987) | | | |
| HOMA-IR quartile† | | | |
| Quartile 1 | 52188 | 342 | 0.92 (0.81-1.05) |
| Quartile 2 | 52187 | 307 | 0.91 (0.79-1.04) |
| Quartile 3 | 52533 | 344 | 1.02 (0.90-1.16) |
| Quartile 4 | 52343 | 402 | 1.21 (1.07-1.37) |
| Diabetes (n=16034) | | | |
| HOMA-IR quartile† | | | |
| Quartile 1 | 14227 | 128 | 1.07 (0.89-1.30) |
| Quartile 2 | 14351 | 130 | 1.14 (0.94-1.38) |
| Quartile 3 | 14331 | 147 | 1.36 (1.14-1.63) |
| Quartile 4 | 14478 | 189 | 1.75 (1.49-2.05) |

Glucose tolerance status was defined by different combinations of glycemic

parameters along with a self-reported previous diagnosis of diabetes by health care professionals, according to the ADA 2010 criteria. There were 111572 participants included in the analysis of glucose tolerance status defined by fasting and 2h glucose, 111574 participants included in the analysis of glucose tolerance status defined by fasting glucose and HbA1c, and 111575 participants included in the analysis of glucose tolerance status defined by 2h glucose and HbA1c.

*HRs (95% CIs) were adjusted for age, sex, education attainment (below high school, high school or above), alcohol drinking status (never, former, current), smoking status (never, former, current), physical activity (inactive, insufficiently active, active), and diet quality score.

†Sex-specific quartiles of HOMA-IR were defined among participants with prediabetes and diabetes, separately.

Abbreviations: CI=confidence interval; CVD=cardiovascular disease;

HbA1c=hemoglobin A1c; HOMA-IR=homoeostasis model assessment of insulin resistance; HR=hazard ratio.

Supplementary Table 8. Hazard ratio (95% CI) of CVD events associated with insulin resistance and obesity in prediabetes or diabetes compared with the overall normal glucose tolerance defined by different combinations of glycemic parameters

| Category | Person-years | Cases | HR (95% CI)* |
|----------------------------------------------------------------------|--------------|-------|------------------|
| Glucose tolerance status defined by fasting and 2h glucose | | | |
| Normal glucose tolerance (n=50632) | 185429 | 1054 | 1.00 (Ref.) |
| Prediabetes (n=46752) | | | |
| HOMA-IR quartile and obesity status† | | | |
| Quartile 1 non-obese | 29185 | 172 | 0.82 (0.70-0.97) |
| obese | 11949 | 91 | 1.04 (0.84-1.29) |
| Quartile 2 non-obese | 22077 | 131 | 0.92 (0.77-1.11) |
| obese | 19173 | 113 | 0.88 (0.72-1.07) |
| Quartile 3 non-obese | 16563 | 84 | 0.81 (0.65-1.01) |
| obese | 25201 | 197 | 1.20 (1.03-1.40) |
| Quartile 4 non-obese | 9587 | 68 | 1.13 (0.88-1.44) |
| obese | 32448 | 244 | 1.18 (1.02-1.35) |
| Diabetes (n=14188) | | | |
| HOMA-IR quartile and obesity status† | | | |
| Quartile 1 non-obese | 7598 | 83 | 1.27 (1.02-1.59) |
| obese | 4973 | 47 | 1.17 (0.87-1.57) |
| Quartile 2 non-obese | 4896 | 38 | 0.99 (0.71-1.36) |
| obese | 7752 | 67 | 1.14 (0.89-1.46) |
| Quartile 3 non-obese | 3315 | 39 | 1.62 (1.18-2.24) |
| obese | 9261 | 111 | 1.61 (1.32-1.96) |
| Quartile 4 non-obese | 2214 | 35 | 2.02 (1.44-2.83) |
| obese | 10522 | 134 | 1.70 (1.42-2.04) |
| Glucose tolerance status defined by fasting glucose and HbA1c | | | |
| Normal glucose tolerance (n=32032) | 117366 | 675 | 1.00 (Ref.) |
| Prediabetes (n=65851) | | | |
| HOMA-IR quartile and obesity status† | | | |
| Quartile 1 non-obese | 42496 | 269 | 0.84 (0.73-0.97) |
| obese | 16227 | 125 | 1.03 (0.85-1.25) |
| Quartile 2 non-obese | 33523 | 190 | 0.82 (0.70-0.97) |
| obese | 25239 | 142 | 0.81 (0.68-0.97) |
| Quartile 3 non-obese | 25010 | 137 | 0.82 (0.68-0.98) |
| obese | 34240 | 231 | 0.99 (0.85-1.15) |
| Quartile 4 non-obese | 14269 | 98 | 1.04 (0.84-1.29) |
| obese | 45012 | 348 | 1.14 (1.01-1.30) |
| Diabetes (n=13691) | | | |
| HOMA-IR quartile and obesity status† | | | |
| Quartile 1 non-obese | 6787 | 51 | 0.90 (0.67-1.19) |
| obese | 5335 | 43 | 0.97 (0.71-1.32) |
| Quartile 2 non-obese | 4375 | 27 | 0.75 (0.51-1.11) |
| obese | 7864 | 67 | 1.05 (0.82-1.35) |
| Quartile 3 non-obese | 2844 | 32 | 1.47 (1.03-2.10) |
| obese | 9302 | 109 | 1.48 (1.21-1.81) |

| | | | |
|-----------------------------------------------------------------|--------|-----|------------------|
| Quartile 4 non-obese | 2014 | 31 | 1.78 (1.24-2.55) |
| obese | 10248 | 133 | 1.65 (1.37-1.99) |
| Glucose tolerance status defined by 2h glucose and HbA1c | | | |
| Normal glucose tolerance (n=37554) | 135515 | 719 | 1.00 (Ref.) |
| Prediabetes (n=57987) | | | |
| HOMA-IR quartile and obesity status† | | | |
| Quartile 1 non-obese | 37862 | 230 | 0.86 (0.74-0.99) |
| obese | 14326 | 112 | 1.11 (0.90-1.35) |
| Quartile 2 non-obese | 29396 | 170 | 0.90 (0.76-1.06) |
| obese | 22791 | 137 | 0.93 (0.77-1.11) |
| Quartile 3 non-obese | 21761 | 132 | 0.95 (0.79-1.15) |
| obese | 30772 | 212 | 1.07 (0.92-1.25) |
| Quartile 4 non-obese | 12326 | 84 | 1.10 (0.87-1.38) |
| obese | 40016 | 318 | 1.25 (1.10-1.43) |
| Diabetes (n=16034) | | | |
| HOMA-IR quartile and obesity status† | | | |
| Quartile 1 non-obese | 8593 | 83 | 1.14 (0.91-1.43) |
| obese | 5634 | 45 | 0.98 (0.72-1.32) |
| Quartile 2 non-obese | 5204 | 42 | 0.97 (0.71-1.32) |
| obese | 9147 | 88 | 1.25 (1.00-1.56) |
| Quartile 3 non-obese | 3619 | 36 | 1.31 (0.94-1.83) |
| obese | 10712 | 111 | 1.38 (1.13-1.69) |
| Quartile 4 non-obese | 2137 | 28 | 1.75 (1.20-2.56) |
| obese | 12342 | 161 | 1.75 (1.47-2.08) |

Glucose tolerance status was defined by different combinations of glycemic parameters along with a self-reported previous diagnosis of diabetes by health care professionals, according to the ADA 2010 criteria. There were 111572 participants included in the analysis of glucose tolerance status defined by fasting and 2h glucose, 111574 participants included in the analysis of glucose tolerance status defined by fasting glucose and HbA1c, and 111575 participants included in the analysis of glucose tolerance status defined by 2h glucose and HbA1c.

*HRs (95% CIs) were adjusted for age, sex, education attainment (below high school, high school or above), alcohol drinking status (never, former, current), smoking status (never, former, current), physical activity (inactive, insufficiently active, active), and diet quality score.

†Sex-specific quartiles of HOMA-IR were defined among participants with prediabetes and diabetes, separately. Obesity was defined as general obesity (BMI ≥ 27.5 kg/m²) or abdominal obesity (waist circumference ≥ 90 cm in men and ≥ 80 cm in women).

Abbreviations: CI=confidence interval; CVD=cardiovascular disease; HbA1c=hemoglobin A1c; HOMA-IR=homoeostasis model assessment of insulin resistance; HR=hazard ratio.

Supplementary Table 9. Hazard ratio (99% CI) of CVD events associated with insulin resistance and the combination of insulin resistance and obesity

| Analysis | HR (99% CI)* | P value |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|---------|
| CVD risk associated with insulin resistance by glucose tolerance status (corresponding to Table 2) | | |
| Normal glucose tolerance (n=28890) | | |
| HOMA-IR quartile† | | |
| Quartile 1 | 1.00 (Ref.) | - |
| Quartile 2 | 0.94 (0.70-1.28) | 0.63 |
| Quartile 3 | 0.96 (0.70-1.30) | 0.70 |
| Quartile 4 | 1.03 (0.76-1.40) | 0.78 |
| Each 1-SD increment in HOMA-IR‡ | 1.04 (0.89-1.22) | 0.50 |
| Prediabetes (n=64972) | | |
| HOMA-IR quartile† | | |
| Quartile 1 | 1.00 (Ref.) | - |
| Quartile 2 | 0.94 (0.78-1.15) | 0.44 |
| Quartile 3 | 1.10 (0.91-1.33) | 0.19 |
| Quartile 4 | 1.23 (1.02-1.48) | 0.0039 |
| Each 1-SD increment in HOMA-IR‡ | 1.12 (1.04-1.20) | <0.0001 |
| Diabetes (n=17714) | | |
| HOMA-IR quartile† | | |
| Quartile 1 | 1.00 (Ref.) | - |
| Quartile 2 | 1.02 (0.75-1.40) | 0.85 |
| Quartile 3 | 1.36 (1.01-1.82) | 0.0080 |
| Quartile 4 | 1.61 (1.21-2.14) | <0.0001 |
| Each 1-SD increment in HOMA-IR‡ | 1.15 (1.08-1.23) | <0.0001 |
| CVD risk associated with insulin resistance in prediabetes or diabetes versus normal glucose tolerance (corresponding to Figure 1) | | |
| Normal glucose tolerance (n=28890) | 1.00 (Ref.) | - |
| Prediabetes (n=64972) | | |
| HOMA-IR quartile† | | |
| Quartile 1 | 0.92 (0.78-1.09) | 0.22 |
| Quartile 2 | 0.87 (0.72-1.04) | 0.040 |
| Quartile 3 | 1.01 (0.85-1.20) | 0.85 |
| Quartile 4 | 1.13 (0.96-1.34) | 0.058 |
| Diabetes (n=17714) | | |
| HOMA-IR quartile† | | |
| Quartile 1 | 1.05 (0.82-1.34) | 0.60 |
| Quartile 2 | 1.08 (0.84-1.39) | 0.42 |
| Quartile 3 | 1.45 (1.16-1.82) | <0.0001 |
| Quartile 4 | 1.71 (1.39-2.11) | <0.0001 |
| CVD risk associated with insulin resistance and obesity in prediabetes or diabetes versus normal glucose tolerance (corresponding to Figure 2) | | |
| Normal glucose tolerance (n=28890) | 1.00 (Ref.) | - |
| Prediabetes (n=64972) | | |
| HOMA-IR quartile and obesity status† | | |
| Quartile 1 non-obese | 0.85 (0.70-1.04) | 0.037 |
| obese | 1.11 (0.86-1.44) | 0.31 |

| | | | |
|--------------------------------------------------|-----------|------------------|---------|
| Quartile 2 | non-obese | 0.83 (0.67-1.04) | 0.035 |
| | obese | 0.91 (0.72-1.16) | 0.32 |
| Quartile 3 | non-obese | 0.96 (0.76-1.21) | 0.64 |
| | obese | 1.06 (0.86-1.30) | 0.50 |
| Quartile 4 | non-obese | 1.03 (0.77-1.37) | 0.82 |
| | obese | 1.17 (0.97-1.40) | 0.027 |
| Diabetes (n=17714) | | | |
| HOMA-IR quartile and obesity status [†] | | | |
| Quartile 1 | non-obese | 1.13 (0.85-1.51) | 0.28 |
| | obese | 0.93 (0.63-1.37) | 0.62 |
| Quartile 2 | non-obese | 0.85 (0.56-1.30) | 0.33 |
| | obese | 1.23 (0.92-1.64) | 0.069 |
| Quartile 3 | non-obese | 1.50 (1.01-2.23) | 0.0082 |
| | obese | 1.44 (1.11-1.85) | 0.0008 |
| Quartile 4 | non-obese | 1.77 (1.14-2.74) | <0.0001 |
| | obese | 1.70 (1.36-2.14) | <0.0001 |

Glucose tolerance status was defined by all three glycemic parameters along with a self-reported previous diagnosis of diabetes by health care professionals, according to the ADA 2010 criteria. There were 111576 participants included in the analysis.


*HRs (99% CIs) were adjusted for age, sex, education attainment (below high school, high school or above), alcohol drinking status (never, former, current), smoking status (never, former, current), physical activity (inactive, insufficiently active, active), and diet quality score.

[†]Sex-specific quartiles of HOMA-IR were defined among participants with prediabetes and diabetes, separately. Obesity was defined as general obesity (BMI ≥ 27.5 kg/m²) or abdominal obesity (waist circumference ≥ 90 cm in men and ≥ 80 cm in women).

[‡]1-SD of HOMA-IR was 1.23 in men and 1.18 in women.

Abbreviations: CI=confidence interval; CVD=cardiovascular disease; HOMA-IR=homoeostasis model assessment of insulin resistance; HR=hazard ratio; SD=standard deviation.

Supplementary Figure 1. Hazard ratio (95% CI) of CVD events associated with insulin resistance and general obesity among participants with prediabetes or diabetes compared with the overall participants with normal glucose tolerance



Glucose tolerance status was defined by all three glycemic parameters along with a self-reported previous diagnosis of diabetes by health care professionals, according to the ADA 2010 criteria. Person-years might not add to total because of rounding. There were 111576 participants included in the analysis.


Sex-specific quartiles of HOMA-IR were defined among participants with prediabetes and diabetes, separately.

General obesity was defined as BMI ≥ 27.5 kg/m².

HRs (95% CIs) were adjusted for age, sex, education attainment (below high school, high school or above), alcohol drinking status (never, former, current), smoking status (never, former, current), physical activity (inactive, insufficiently active, active), and diet quality score.

Abbreviations: CI=confidence interval; CVD=cardiovascular disease; HOMA-IR=homoeostasis model assessment of insulin resistance; HR=hazard ratio.

Supplementary Figure 2. Hazard ratio (95% CI) of CVD events associated with insulin resistance and abdominal obesity among participants with prediabetes or diabetes compared with the overall participants with normal glucose tolerance



Glucose tolerance status was defined by all three glycemic parameters along with a self-reported previous diagnosis of diabetes by health care professionals, according to the ADA 2010 criteria. Person-years might not add to total because of rounding. There were 111576 participants included in the analysis.

Sex-specific quartiles of HOMA-IR were defined among participants with prediabetes and diabetes, separately.

Abdominal obesity was defined as waist circumference ≥ 90 cm in men and ≥ 80 cm in women.

HRs (95% CIs) were adjusted for age, sex, education attainment (below high school, high school or above), alcohol drinking status (never, former, current), smoking status (never, former, current), physical activity (inactive, insufficiently active, active), and diet quality score.

Abbreviations: CI=confidence interval; CVD=cardiovascular disease; HOMA-IR=homoeostasis model assessment of insulin resistance; HR=hazard ratio.